NPCE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.55%, SMA50 -4.99%, SMA200 19.74%). The stock’s 14-day RSI is 47.35 (neutral), while the ATR of 0.72 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.84% below its high and over 98.61% above its low. Average 10-day trading volume of 318.55 thousand shares is significantly above the 3-month average of 203.32 thousand, indicating heightened recent market interest.

NeuroPace, Inc. has 33.08 million shares outstanding. The public float is 22.52 million shares, elevated short interest at 5.73% of float. This equals 1.11 million shares. The short ratio is 4.81 days. Institutional investors hold 97.66% of the float. Insiders own 2.68%. Accelmed Partners II L.P. holds 4.43 million shares, ORBIMED ADVISORS LLC has 3.24 million shares and Norton Evan has 588.24 thousand shares. Over the past six months, insider transactions show net selling. They sold 25.00 thousand shares across 1 transactions.

NeuroPace, Inc. generated EPS of -$0.75 over the past year. Five-year average earnings growth is 5.83%. Wall Street analysts project EPS growth of 23.62% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.16. Next year's EPS is expected at $6.96. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $15.00. The high target offers 43.23% upside. The low target suggests -2.34% downside. The mean target is $18.57. This offers 20.9% upside. NeuroPace, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -30.57%. The prior quarter beat by -42.86%. Over the last six quarters, Apple has recorded several small beats. These include -28.0% in March 04, 2025.

NeuroPace, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

NeuroPace, Inc. (NASDAQ:NPCE) closed at $15.36 USD, losing -$0.43 (-2.72%) from the previous close of $15.79. The stock is currently mid-range between its 52-week high and low $7.56 and $19.60. With a market capitalization of about $523.68 million, NeuroPace, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.93). Key stats such as the average daily volume over the past year has been around 211.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Mountain View, CA, NeuroPace, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Joel D. Becker, the company employs approximately 184 people and listed since April 22, 2021. NeuroPace, Inc. operates as a medical device company in the United States.

NeuroPace, Inc. (NASDAQ:NPCE) shares are flat 6.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NeuroPace, Inc. trading at a premium to the broader market with a P/E of -23.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.65, suggesting -4.62% downside. Our AI forecast model points to short-term strength (4.17% over two weeks), a medium-term fall (-41.21% over three months), and a longer-term gain (21.22% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NeuroPace, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.17%, with price expected at $16.00 by May 29, 2026, within a range of $15.07 to $16.87 3-Month Outlook: Projected fall of -41.21%, reaching $9.03 by August 12, 2026, with a range of $8.55 to $9.42. 1-Year Outlook: Projected gain of 21.22%, with price at $18.62 by May 14, 2027, within a range of $17.53 to $19.79.

NeuroPace, Inc. trades at a P/E ratio of -23.58, slightly below the S&P 500 average, with a price-to-sales ratio of 5.17 and a price-to-book ratio of 35.18 reflecting a rich premium to book value. The P/FCF stands at -52.27, also below market averages. Compared to sector medians, NeuroPace, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.